{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=85",
    "query": {
      "intervention": "Protein Control",
      "page": 85
    },
    "page_size": 10
  },
  "pagination": {
    "page": 85,
    "page_size": 10,
    "total_count": 3500,
    "total_pages": 350,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=86&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=84&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T18:50:59.391Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03675477",
      "title": "A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "SHR0302",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reistone Biopharma Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 164,
      "start_date": "2019-04-13",
      "completion_date": "2021-02-03",
      "has_results": true,
      "last_update_posted_date": "2023-06-02",
      "last_synced_at": "2026-11-07T18:50:59.391Z",
      "location_count": 3,
      "location_summary": "Lake Wales, Florida • Tampa, Florida • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Lake Wales",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03675477"
    },
    {
      "nct_id": "NCT00779701",
      "title": "Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Temple University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2007-03",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2017-03-16",
      "last_synced_at": "2026-11-07T18:50:59.391Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00779701"
    },
    {
      "nct_id": "NCT01539512",
      "title": "A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Idelalisib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match idelalisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2012-04",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2019-05-14",
      "last_synced_at": "2026-11-07T18:50:59.391Z",
      "location_count": 34,
      "location_summary": "Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 27 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01539512"
    },
    {
      "nct_id": "NCT06565611",
      "title": "A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "bremelanotide",
          "type": "DRUG"
        },
        {
          "name": "tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Palatin Technologies, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 108,
      "start_date": "2024-08-05",
      "completion_date": "2025-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-11-07T18:50:59.391Z",
      "location_count": 4,
      "location_summary": "DeLand, Florida • Oklahoma City, Oklahoma • North Charleston, South Carolina + 1 more",
      "locations": [
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "North Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06565611"
    },
    {
      "nct_id": "NCT05773053",
      "title": "A Study of NT 201 Doses in the Treatment of Platysma Prominence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Platysma Prominence"
      ],
      "interventions": [
        {
          "name": "NT 201",
          "type": "DRUG"
        },
        {
          "name": "NT 201 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz Aesthetics GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 73,
      "start_date": "2023-03-22",
      "completion_date": "2024-01-24",
      "has_results": false,
      "last_update_posted_date": "2024-10-21",
      "last_synced_at": "2026-11-07T18:50:59.391Z",
      "location_count": 7,
      "location_summary": "Washington D.C., District of Columbia • Aventura, Florida • Coral Gables, Florida + 3 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "Verona",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05773053"
    },
    {
      "nct_id": "NCT03773172",
      "title": "Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "MEDI6012",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 7,
      "start_date": "2019-01-31",
      "completion_date": "2020-08-31",
      "has_results": true,
      "last_update_posted_date": "2024-11-12",
      "last_synced_at": "2026-11-07T18:50:59.391Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03773172"
    },
    {
      "nct_id": "NCT02059811",
      "title": "Efficacy and Safety of the DASH Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "DASH Diet",
          "type": "OTHER"
        },
        {
          "name": "Control Diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2014-02",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2014-10-03",
      "last_synced_at": "2026-11-07T18:50:59.391Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02059811"
    },
    {
      "nct_id": "NCT02849457",
      "title": "Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tuberous Sclerosis Complex"
      ],
      "interventions": [
        {
          "name": "Early Vigabatrin",
          "type": "DRUG"
        },
        {
          "name": "Delayed Vigabatrin (Placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Martina Bebin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "6 Months",
        "sex": "ALL",
        "summary": "1 Day to 6 Months"
      },
      "enrollment_count": 84,
      "start_date": "2016-12",
      "completion_date": "2023-05-05",
      "has_results": true,
      "last_update_posted_date": "2024-08-19",
      "last_synced_at": "2026-11-07T18:50:59.391Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02849457"
    },
    {
      "nct_id": "NCT00044057",
      "title": "A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "YM872 (zonampanel), t-PA (alteplase)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-12",
      "completion_date": "2003-01",
      "has_results": false,
      "last_update_posted_date": "2006-04-03",
      "last_synced_at": "2026-11-07T18:50:59.391Z",
      "location_count": 94,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 78 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00044057"
    },
    {
      "nct_id": "NCT06091865",
      "title": "A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma (DLBCL)"
      ],
      "interventions": [
        {
          "name": "Odronextamab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone/Prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 904,
      "start_date": "2023-12-13",
      "completion_date": "2029-09-12",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-07T18:50:59.391Z",
      "location_count": 23,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Orange, California + 19 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06091865"
    }
  ]
}